Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135258 | 0.91 | C5AR1 (0.45) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5361073 | 0.90 | KMT2A (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5137536 | 0.87 | ALDH1A1 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5136802 | 0.87 | OPRM1 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5135858 | 0.85 | TACR1 (0.39) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5137411 | 0.85 | ALDH1A1 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5137520 | 0.83 | PKM (0.39) | CYP2D6HTR1AHTR7DRD3 | |
| SCHEMBL5354239 | 0.83 | HTR2A (0.45) | ALDH1A1 | |
| SCHEMBL5135607 | 0.83 | OPRM1 (0.45) | SLC6A2SLC6A3HTR1AHTR7 | |
| SCHEMBL5365491 | 0.82 | HTT (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-03-11 | — | — | US | claimed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7148225-B2 | Substituted biaryl amides as C5A receptor modulators | NEUROGEN CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2006-08-10 | — | — | US | disclosed |
| EP-1487796-A4 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-05-05 | — | — | US | disclosed |
| US-6858637-B2 | Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide | NEUROGEN CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1487796-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082826-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | SLC6A2 1971/4885SLC6A4 2648/4885SLC6A3 3617/4885 |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | C5AR1, C5AR2, C3AR1 | SLC6A2 1929/4885SLC6A4 2621/4885SLC6A3 3550/4885 |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | SLC6A2 1929/4885SLC6A4 2621/4885SLC6A3 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.